Cardiac contractility modulation is a therapy which is intended for the treatment of patients with moderate to severe heart failure (NYHA class II–IV) with symptoms despite optimal medical therapy who can benefit from an improvement in cardiac output.

2022年3月14日 · CCM therapy delivers nonexcitatory biphasic electric signals (7.5 V/22 ms duration) to the right ventricular septum during the absolute refractory period of the cardiac cycle; this improves calcium homeostasis in myocytes and initiates reverse programing of fetal gene expression observed in heart failure. 1,2 The mechanism of benefit is ...

2018年12月10日 · Cardiac contractility modulation (CCM) is a device-based therapy for heart failure (HF) that involves applying relatively high-voltage (≈7.5 V), long-duration (≈20 milliseconds), biphasic electric signals to the right ventricular septal wall during the absolute myocardial refractory period.

2024年1月31日 · CCM is a device-based therapy to treat patients with symptomatic heart failure. “The goal of this device is to provide electrical impulses during a particular time of the cardiac cycle or heartbeat,” says advanced heart failure and transplant cardiologist Scott Lundgren, DO .

In recent years, a new therapy—cardiac contractility modulation (CCM)—has become available. This therapy delivers high amplitude non-excitatory biphasic electrical signals during the myocardial refractory period.

Cardiac contractility modulation (CCM) has been shown to benefit patients with class III systolic heart failure with an ejection fraction of 25%–45% not indicated for biventricular pacing. Despite the increased use of CCM, there is a significant knowledge deficit in the general electrophysiology community regarding its clinical management.

Cardiac Contractility Modulation is a therapy which is intended for the treatment of patients with moderate to severe chronic heart failure (NYHA class III–IV), LVEF 25-45% and QRS <130ms with symptoms despite optimal medical therapy.

2023年11月1日 · Cardiac contractility modulation (CCM) is a Food and Drug Administration-approved device-based therapy for patients with heart failure. The system delivers biphasic electric stimulation to the ventricular myocardium during the absolute refractory period to augment left ventricular contraction.

Background: Cardiac contractility modulation (CCM) is a treatment option for patients suffering symptomatic chronic heart failure (CHF) with reduced left ventricular ejection fraction (LVEF) who are not eligible for cardiac resynchronization. Data on mid-term follow-up are limited to small observational studies.

European Clinical trials have shown that chronic Cardiac Contractility Modulation treatment is safe and significantly improves exercise tolerance and quality of life in symptomatic heart failure patients with normal QRS duration.